Please contact us for more information or to learn if you are eligible to participate.
To demonstrate that LOU064 (100 mg PO bid) is superior to teriflunomide (14 mg PO once daily) in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in Participants with relapsing MS.
Principal Investigator | Roberto A. Cruz Saldana, M.D. |
Co-PI | Esmeralda Cordoso-Mendoza |
Sponsor | Novartis |
Type of Trial | Interventional |